A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice.
Studies in gene-targeted mice have demonstrated that factor B of the alternative complement pathway plays an important role in several disease models, but an exogenous inhibitor of factor B has not previously been available. We have developed an inhibitory monoclonal antibody directed against a critical epitope on mouse factor B and have tested it in a model of antiphospholipid (aPL) antibody (Ab)-induced fetal loss. Gene-targeted factor B-deficient mice (fB-/-) were injected with a fusion protein comprised of the second and third short consensus repeat (SCR) domains of mouse factor B linked to a mouse IgG1 Fc domain. Hybridomas were made from splenocytes of the immunized mouse. One mAb, designated 1379, produced an IgG1 antibody that inhibited alternative pathway activation in vitro and in vivo by preventing formation of the C3bBb complex. Strikingly, this mAb inhibited alternative pathway activation in serum from mice, rats, humans, monkeys, pigs and horses. Fab fragments made from this mAb also inhibited alternative pathway activation. Epitope mapping demonstrated that this antibody binds to factor B within the third SCR domain. When mAb 1379 was administered to mice that also received human IgG containing antiphospholipid antibodies, it provided significant protection from antiphospholipid antibody-induced complement activation and fetal loss. Thus, this mAb to factor B has broad species reactivity and effectively inhibits alternative pathway activation. The mAb protects mice in an in vivo model of antiphospholipid antibody syndrome, demonstrating the therapeutic potential for the inhibition of factor B in this disease.
Thurman
Joshua M
JM
Division of Nephrology and Hypertension, University of Colorado Health Sciences Center, 4200 E. 9th Avenue, B-115, Denver, CO 80262, USA. joshua.thurman@uchsc.edu
Kraus
Damian M
DM
Girardi
Guillermina
G
Hourcade
Dennis
D
Kang
Hee J
HJ
Royer
Pamela A
PA
Mitchell
Lynne M
LM
Giclas
Patricia C
PC
Salmon
Jane
J
Gilkeson
Gary
G
Holers
V Michael
VM
D000818:Animals; D017152:Antibodies, Antiphospholipid / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D003167:Complement Activation / Q000187:drug effects*; D011415:Complement Factor B / Q000037:antagonists & inhibitors / Q000276:immunology; D004195:Disease Models, Animal; D018604:Epitope Mapping; D005260:Female; D005313:Fetal Death / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy
D017152:Antibodies, Antiphospholipid; D000911:Antibodies, Monoclonal; D011415:Complement Factor B